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Summary
Severe acute respiratory syndrome (SARS) is caused
by a newly emerged coronavirus that infected more
than 8000 individuals and resulted in more than 800 fa-
talities in 2003. Currently, there is no effective treat-
ment for this epidemic. SARS-3CLpro has been shown
to be essential for replication and is thus a target for
drug discovery. Here, a class of stable benzotriazole
esters was reported as mechanism-based inactivators
of 3CLpro, and the most potent inactivator exhibited
a kinact of 0.0011 s
21 and a Ki of 7.5 nM. Mechanistic in-
vestigation with kinetic and mass spectrometry analy-
ses indicates that the active site Cys145 is acylated,
and that no irreversible inactivation was observed
with the use of the C145A mutant. In addition, a non-
covalent, competitive inhibition became apparent by
using benzotriazole ester surrogates in which the
bridged ester-oxygen group is replaced with carbon.
Introduction
Severe acute respiratory syndrome (SARS), a newly
emerged infectious disease, first occurred in Guandong
(China) in November of 2002 and spread through many
countries in 2003; it reemerged in China in December
2003 and in the spring of 2004. This disease is caused
by infection with a novel human coronavirus (SARS-
CoV) [1–3], which affected more than 8000 individuals
*Correspondence: phliang@gate.sinica.edu.tw (P.-H.L.); wong@
scripps.edu (C.-H.W.)across 32 countries and resulted in more than 800 fatal-
ities in 2003 [4–6]. The origin of SARS-CoV is unclear,
though studies on the molecular evolution of SARS-
CoV indicate that the virus may have emerged from non-
human species [7]. At present, no efficacious therapy for
SARS is available. Therefore, a search for effective anti-
virals for the SARS-CoV is of current interest.
SARS coronavirus is a positive-strand RNA virus that
encodes two polyproteins, pp1a and pp1ab [8–10], for
further proteolytic processing to provide the functional
proteins for viral propagation. These processes are me-
diated primarily by the main protease (Mpro), known as
dimeric chymotrypsin-like protease (3CLpro) [11–13].
The active site of 3CLpro contains Cys145 and His41,
constituting a catalytic dyad in which the cysteine thiol
functions as the nucleophile in the proteolytic process
[11–13]. Due to its essential role in viral replication, the
protease is an attractive target for the development of
therapeutics against SARS.
So far, only a few inhibitors of 3CLpro have been re-
ported, including the HIV protease inhibitor TL-3 [14],
zinc-conjugated compounds [15], aryl boronic acids
analogs [16], a quinolinecarboxylate derivative [17], a
thiophenecarboxylate [18], phthalhydrazide-substituted
keto-glutamine analogs [19], and anilides [20]. How-
ever, none of these inhibitors exhibits activities in the
low nanomolar range, and no preclinical studies were
reported.
As a part of our efforts directed toward the develop-
ment of potent anti-SARS agents, we report here the dis-
covery of a new class of mechanism-based irreversible
inactivators with inhibition constants in the nanomolar
range, by using the strategy of combinatorial reaction
in microtiter plates followed by screening in situ [21–
23]. This approach relies on the use of high-yield organic
reactions that can be carried out in water or water-mis-
cible, nontoxic solvents on microscales without protect-
ing groups, allowing the product to be assayed directly
in situ without isolation and purification. Using this
approach, one can quickly modify a lead compound
with a small set of building blocks to identify an optimal
inhibitor.
Results and Discussion
Previously [14], we have reported that the HIV protease
inhibitor Lopinavir (Figure 1) also inhibits 3CLpro with an
IC50 of w50 mM. In order to find more potent 3CL
pro in-
hibitors, a library of Lopinavir-like compounds was as-
sembled by using either diamine 1 or amine 2 as the
core structure [24] for reaction with various acids in mi-
crotiter plates followed by screening in situ (Figure 1). In
a typical procedure [21–23], a library of 90 carboxylic
acids (see the Supplemental Data available with this ar-
ticle online) (10 mmol each) in a microtiter plate was used
to couple with amine 1 or 2 (10 mmol) in the presence
of N,N-diisopropylethylamine (22 mmol) and 2-(1H-ben-
zotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-
phosphate (HBTU, 11 mmol) in DMF (100 ml) for 4 hr. An
aliquot of the product, based on a putative 100%
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262Figure 1. Microtiter Plate-Based Reactions
and In Situ Screening
(A) Reactions of 1 or 2 with 90 acids in micro-
titer plates, followed by in situ screening for
inhibitors of SARS-CoV 3CLpro.
(B) Reactions of HBTU and 90 acids in mi-
crotiter plates, followed by in situ screening
for inhibitors of SARS-CoV 3CLpro.
(C) Molecular structures of inhibitors 3–10
against SARS-CoV 3CLpro.conversion of starting materials, was taken and sub-
jected to the 3CLpro inhibition assay in a 20 mM Bis-
Tris buffer (pH 7.0) at 25ºC. To obtain the IC50 values,
the initial velocities of the inhibited reactions with 50
nM of the protease and 6 mM of a fluorogenic substrate
were plotted against different inhibitor concentrations.
In this study, we noticed that the products derived
from 2-aminobenzoic acid (well C9, IC50 = 0.2 mM), 4-
(methylamino)benzoic acid (well D5, IC50 = 0.3 mM), 4-
(dimethylamino)benzoic acid (well D6, IC50 = 0.5 mM),
and 4-(diethylamino)benzoic acid (well D7, IC50 = 0.5
mM) showed the best inhibition and that the degree of in-
hibition was independent of the amine used.
In order to characterize the inhibitors, we attempted to
separately prepare the pure amide derivatives, but we
found that the amide formation was very slow, and
that the intermediates benzotriazole esters 326 were
isolated as major products from silica gel columns (the
X-ray ORTEP structure of compound 4 is shown in the
Supplemental Data). To our surprise, all of the Lopina-
vir-like compounds showed only modest inhibitory ac-
tivities toward 3CLpro (IC50 R 10 mM), whereas benzo-
triazole esters 326 showed high inhibition activities.
To our knowledge, benzotriazole esters have been
used as acylating agents and have never been found
to be enzyme inhibitors. We then prepared a series of
benzotriazole esters by condensation of HBTU with var-
ious carboxylic acids (Figure 1B), and we found that the
benzotriazole esters derived from benzoic acid contain-
ing electron-withdrawing substituents, e.g., NO2, CN,
and CF3, were susceptible to hydrolysis, whereas ben-
zotriazole esters 3–6 and those with electron-donating
groups were relatively stable in pH 5.0–8.0 over 24 hrat room temperature. The relative stability of each deriv-
ative depends on the pKa of the corresponding benzoic
acid and basically follows the Hammett equation [25–
27]. These stable benzotriazole esters, esters 3–10
(Figure 1C), were assayed, and their inhibition results
against 3CLpro are shown in Table 1.
Further study of the inhibition of benzotriazole esters
3–10 showed that there was a time-dependent decrease
in enzyme activity as a function of the inhibitor concen-
tration (e.g., the inhibition of compound 4) (Figure 2A). In
the presence of 1 mM DTT (dithiothreitol), the preincu-
bation of enzyme with inhibitor did not affect the enzyme
activity, indicating that DTT can protect the enzyme from
inactivation (Figure 2B). These experiments indicate an
irreversible mode of action and point to the active site
Cys being involved in the inactivation process. The ki-
netic results for kinact and Ki determinations of com-
pound 4 are shown in Figures 2C and 2D (the detailed
Table 1. IC50, Ki, kinact, and CC50 of Benzotriazole Esters
Compounds
Ki
(nM)
kinact
(s21) 3 103
kinact/Ki
(M21s21) 3 1023
CC50
(mM)
3 19.5 1.6 82.0 >100
4 17.4 1.3 74.7 >100
5 12.1 0.9 74.4 >100
6 11.1 0.8 72.1 >100
7 22.9 1.1 48.0 >100
8 7.5 1.1 146.7 >100
9 12.3 0.9 73.2 >100
10 13.8 1.2 86.9 >100
CC50: The concentration that causes 50% cytotoxicity.
SARS 3CLpro Inhibited by Benzotriazole Esters
263Figure 2. Kinetic Studies of Inhibitor 4 and
SARS-CoV 3CLpro
(A) The progress curves in the presence of
0.3–3.0 mM inhibitor for reactions initiated
by adding enzyme (final concentration of
0.05 mM) into a mixture of substrate (6 mM)
and inhibitor 4. Over the entire 5 min time
window, the uninhibited enzyme displayed a
linear progress curve, whereas the inhibited
enzyme with a different concentration of in-
hibitor showed a time-dependent reduction
of activity.
(B) The same experiments as performed in
(A), but with 1 mM DTT in the preincubation
mixture.
(C) Preincubation time dependence of the
fractional velocity of the protease-catalyzed
reaction in the presence of 0.02–0.2 mM time-
dependent inhibitor 4.
(D) Kitz and Wilson replot of the half-life (t1/2)
of enzyme inactivation as a function of the
reciprocal of the slow inactivator concentra-
tion. The kinact is 0.0013 s
21 and Ki is 17.4 nM
for the time-dependent inactivator 4 based
on the kinetic data.procedures are shown in the Supplemental Data). We
used the initial rate of inactivation (0–10 min) showing
pseudo first-order kinetics to determine the inhibition
constants. The enzyme activity is, however, not reduced
to zero over the time period, perhaps because of the de-
composition of the thioester intermediate or the exis-
tence of two populations of the enzymes. As shown in
Table 1, benzotriazole esters 3–10 are strong inhibitors,
and, among these, 8 is the most potent, with an inactiva-
tion constant of 1.1 3 1023 s21 and an inhibition con-
stant of 7.5 nM. In addition, these esters are not toxic
to Vero E6 cells, which are often used in the cell-based
assay for SARS-CoV [14], at a concentration of
100 mM. Compound 8 represents the most potent mech-
anism-based 3CLpro inhibitor reported to date.
We also investigated the nature of the inhibited en-
zyme by mass spectrometry. Electrospray ionization
mass spectra of wild-type 3CLpro and 3CLpro treated
with 4-(dimethylamino)benzoyl ester 4 (2 hr of incuba-
tion and 18 hr of dialysis) and their deconvoluted mass
spectra were determined (see the Supplemental Data).
The mass difference of 148.6 Da between the peaks of
33847.35 ([M + H]+) and 33995.93 ([M + H]+) implies the
acylation of 3CLpro with a 4-(dimethylamino)benzoyl
moiety (mass 147.12). To further investigate the acyla-
tion site, MALDI-TOF mass spectrometric analysis of
the trypsin digest of 3CLpro and 3CLpro treated with 4-
(dimethylamino)benzoyl ester 4 was performed. From
the MALDI spectra of the tryptic 3CLpro and the tryptic
acylated 3CLpro of G138-K180 peptide fragments, a
mass shift of 147 Da between T15 (4594.11 Da) and ac-
ylated T15 (4741.31 Da) indicates that this peptide frag-
ment contains an acylated residue (Figures 3A and 3B).
In order to determine the acylation site on the acylated
T15 peptide, we performed a sequence analysis by
MALDI MS/MS for peptides T15 and acylated T15 as de-
picted in Figure 3C. There is no mass difference among y
series fragment ions up to y27, but a mass shift of 147.2
Da (4149.6 Da versus 4296.8 Da) on b39 clearly shows
that Cys145 is the only acylation site. This is consistent
with the observation of no mass shift of mutant C145A3CLpro treated with 4-(dimethylamino)benzoyl ester 4.
All of these results support the mechanism of irrevers-
ible inhibition of 3CLpro by 4-(dimethylamino)benzoyl es-
ter 4 via acylation of Cys145 (Figure 4).
In order to develop stable, noncovalent inhibitors
based on the benzotriazole esters discovered in this
study, we synthesized compounds 13 and 14 by using
TBAF-assisted N-alkylation of 1H-benzotriazole 11 [28,
29]. In addition, compound 13 was hydrogenated with
Pd(OH)2/C as a catalyst at room temperature to obtain
compounds 15 (82%) and 16 (13%). Compounds 15
and 16 were methylated or dimethylated to compounds
17–20 by using TBAF as a reagent (Figure 5A). Com-
pounds 13–20 have all the features of benzotriazole es-
ter inhibitors, except that the ester oxygen is replaced
by a carbon. Inhibition analysis shows that compounds
13–20 are noncovalent competitive inhibitors, albeit rel-
atively weak ones compared to the corresponding es-
ters; of these, compound 14 is most potent, with a Ki
of 1.0 mM. Reduction of the carbonyl group, however, re-
sults in a significant loss of activity (Figure 5A). It is noted
that the benzotriazole compounds contain three equilib-
rium structures in solution (Figure 5B) [25, 26], and that
compounds 13–20 may mimic the ester forms instead
of the three equilibrium forms found in solution.
To gain further insight into the mode of inhibition,
a docking experiment based on computer modeling (Au-
todock version 3.0.5) [30] for the binding of compounds
3, 4, 8, and 9 with 3CLpro (1uk4) [12] was carried out, and
the result indicated that the benzotriazole moiety was
disposed in the pocket formed by Cys145, Ser144, and
Gly143 in the active site (Figure 6). The g-S atom of
Cys145 was close enough, within 3.5 A˚ in a rigid model,
to the carbonyl group of the benzotriazole ester to ren-
der a nucleophilic attack. The aminophenyl group (for
3 and 4) and the indole moiety (for 8 and 9) were in the
region surrounded by Thr25, Thr26, His41, Thr45,
Ala46, and Met49. The NH group of the indole moiety
of 8 was hydrogen bonded with the side chain OH of
Thr25. In comparison, the indole group of 9 lacks such
hydrogen bonding and thus shows a weaker affinity
Chemistry & Biology
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265Figure 4. Proposed Mechanism for Inhibition
of SARS-CoV 3CLpro by Acylation with Ben-
zotriazole Esterstoward 3CLpro than does isomer 8. Compounds 13–20
do not fit into the pocket well enough to interact with
the residues mentioned above, and the calculated min-
imal energies of binding are w0.5–1.0 kcal/mol higher
than those of the corresponding esters, consistent
with the inhibition assay result (see the Supplemental
Data).
Significance
Severe acute respiratory syndrome (SARS) is a newly
emerged disease caused by a novel human corona-
virus. Currently, no effective antiviral agents exist
against this deadly epidemic. The main protease of
SARS-CoV, 3CLpro, is an attractive target for drug dis-
covery due to its essential role in viral replication. We
have discovered several stable benzotriazole esters as
a new class of irreversible enzyme inhibitors, and, to
our knowledge, these compounds are the most potent
mechanism-based 3CLpro inhibitors known to date.
The mode of action has been studied and has been
shown to proceed through acylation of the active site
Cys145 assisted by the catalytic dyad.
Experimental Procedures
Materials and Methods
SARS-CoV 3CL protease was prepared according to the previously
described procedure [31]. Reactions requiring dry conditions were
carried out under an inert atmosphere by using standard tech-
niques. All of the reagents and solvents were reagent grade and
were used without further purification unless otherwise specified.
THF was distilled from sodium benzophenone ketyl under N2.
HRMS values were obtained by using the EI as the ionization source.
General Procedure for the Preparation of Benzotriazole Esters
To a solution of acid compound (1.0 equiv.), 2-(1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 1.1
equiv) in DMF (1.0 ml), as well as N,N-diisopropylethylamine (DIEA,
1.1 equiv.), was added. After the solution was stirred at 25ºC for
3.0 hr, the reaction mixture was added to 1 M NaHCO3 (10 ml) and
extracted with ethyl acetate (EA) (15 ml 3 3), and the organic layer
was collected and concentrated under reduced pressure. The resi-
due was purified by use of column chromatography on silica gel to
provide the desired 1-hydroxybenzotriazole esters.
2-Aminobenzoic Acid Benzotriazol-1-yl Ester, 3
The standard procedure was followed by use of 2-aminobenzoic
acid (C9, 34.8 mg, 0.2537 mmol, 1.0 equiv.), HBTU (105.9 mg,
0.2791 mmol, 1.1 equiv.), and DIEA (49 ml, 0.2791 mmol, 1.1 equiv.).
After the reaction mixture was worked up, the residue was purified
by use of column chromatography (5% MeOH in chloroform aseluant). Benzotriazole ester 3 (57.4 mg, 0.2258 mmol) was obtained
in 89% yield as a yellow solid: TLC Rf = 0.81 (5% MeOH in CHCl3 as
eluant); 1H NMR (CDCl3, 400 MHz) d = 5.31 (brs, 2 H, NH2), 6.73–6.78
(m, 2 H, 2 3 ArH), 7.41 (t, 2 H, J = 6.0 Hz, 2 3 ArH), 7.46 (d, 1 H, J =
6.6 Hz, ArH), 7.52 (t, 1 H, J = 6.0 Hz, ArH), 8.06 (d, 2 H, J = 6.7 Hz,
ArH), 8.14 (d, 1 H, J = 6.7 Hz, ArH); 13C NMR (CDCl3, 100 MHz) d =
104.26, 108.45, 116.82, 116.98, 120.42, 124.78, 128.66, 129.00,
130.84, 136.71, 143.50, 152.23, 163.65; IR (KBr) 3456 (m, NH), 3322
(m, NH), 1736 (s, C=O), 1632 (s), 1566 (m), 1485 (s), 1372 (m), 1228
(s), 1153 (s), 977 (s), 740 (s) cm21; HRMS [M + 1] calcd for
C13H11N4O2: 255.0875, found 255.0882.
4-Dimethylamino-Benzoic Acid Benzotriazol-1-yl Ester, 4
The standard procedure was followed by use of (dimethylamino)-
benzoic acid (D6, 120.3 mg, 0.7283 mmol, 1.0 equiv.), HBTU (303.8
mg, 0.8011 mmol, 1.1 equiv.), and DIEA (140 ml, 0.8011 mmol, 1.1
equiv.). After the reaction mixture was worked up, the residue was
purified by use of column chromatography (chloroform as eluant).
Benzotriazole ester 4 (191.2 mg, 0.6773 mmol) was obtained in
93% yield as a light-yellow solid: TLC Rf = 0.50 (CHCl3 as eluant);
1H NMR (CDCl3, 400 MHz) d = 3.13 (s, 6 H, 2 3 CH3), 6.74 (d, J =
8.9 Hz, 2 H, 2 3 ArH), 7.42 (t, J = 6.7 Hz, 1 H, ArH), 7.47–7.55 (m, 2
H, 2 3 ArH), 8.07–8.12 (m, 3 H, 3 3 ArH); 13C NMR (CDCl3, 100
MHz) d = 40.01, 108.64, 110.02, 111.06, 120.35, 124.54, 128.36,
129.11, 132.73, 143.57, 154.38, 163.51; IR (KBr) 2914 (w), 1768 (s,
C=O), 1609 (s), 1537 (s), 1441 (s), 1386 (s), 1263 (s), 1183 (s), 957
(s), 770 (s) cm21; HRMS [M + 1] calcd for C15H15N4O2: 283.1195,
found 283.1199.
4-Methylamino-Benzoic Acid Benzotriazol-1-yl Ester, 5
The standard procedure was followed by use of (4-methylamino)-
benzoic acid (D5, 53.5 mg, 0.3539 mmol, 1.0 equiv.), HBTU (147.7
mg, 0.3894 mmol, 1.1 equiv.), and DIEA (68 ml, 0.3894 mmol, 1.1
equiv.). After the reaction mixture was worked up, the residue was
purified by use of column chromatography (chloroform as eluant).
Benzotriazole ester 5 (88.3 mg, 0.3291 mmol) was obtained in 93%
yield as a white solid: TLC Rf = 0.28 (CHCl3 as eluant);
1H NMR
(CDCl3, 400 MHz) d = 2.92 (d, 3 H, J = 1.5 Hz, CH3N), 6.63 (d, 2 H,
J = 8.7 Hz, 2 3 ArH), 7.41 (t, 1 H, J = 7.6 Hz, ArH), 7.46–7.53 (m,
2 H, 2 3 ArH), 8.04–8.07 (m, 3 H, 3 3 ArH); 13C NMR (CDCl3,
100 MHz) d = 29.91, 108.61, 111.05, 111.52, 120.29, 124.62, 128.43,
129.05, 133.00, 143.52, 154.70, 162.70; IR (KBr) 3346 (m, NH), 3010
(m), 2907 (w), 1764 (s, C=O), 1602 (s), 1545 (s), 1497 (s), 1446 (s),
1362 (s), 1238 (s), 1068 (s), 957 (s), 791 (s) cm21; HRMS [M + 1] calcd
for C14H13N4O2: 269.1039, found 269.1032.
4-Diethylamino-Benzoic Acid Benzotriazol-1-yl Ester, 6
The standard procedure was followed by use of (diethylamino)ben-
zoic acid (D7, 48.4 mg, 0.2505 mmol, 1.0 equiv.), HBTU (104.5 mg,
0.2755 mmol, 1.1 equiv.), and DIEA (48 ml, 0.2755 mmol, 1.1 equiv.).
After the reaction mixture was worked up, the residue was purified
by use of column chromatography (chloroform as eluant). Benzotria-
zole ester 6 (71.5 mg, 0.2304 mmol) was obtained in 92% yield as
a light-yellow solid: TLC Rf = 0.50 (CHCl3 as eluant);
1H NMR
(CDCl3, 400 MHz) d = 1.17–1.25 (m, 6 H, 2 3 CH3), 3.38–3.49 (m,
4 H, 2 3 CH2), 6.70 (d, 2 H, J = 8.8 Hz, 2 3 ArH), 7.40 (t, J = 7.4 Hz,Figure 3. MALDI Spectrum of Inhibitor 4 and SARS 3CLpro
(A) MALDI spectrum of tryptic 3CLpro.
(B) MALDI spectrum of tryptic acylated 3CLpro.
(C) MALDI MS/MS spectra of T15 and acylated T15 peptides (GSFLNGSC*GSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGK) showed a mass
shift of 147.2 Da (4149.6 Da versus 4296.8 Da) on b39, indicating that Cys145 (C*) is the acylation site.
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tors
(A) Synthesis of compounds 13–20 and their
IC50s or Kis for SARS-CoV 3CL
pro.
(B) The equilibrium structures of the benzo-
triazole compounds in solution.1 H, ArH), 7.42–7.53 (m, 2 H, 2 3 ArH), 6.70 (d, 1 H, J = 8.8 Hz, ArH),
8.06 (d, J = 8.8 Hz, 2 H, 23ArH); 13C NMR (CDCl3, 100 MHz) d = 12.39,
44.66, 108.63, 110.64, 120.29, 124.53, 128.33, 128.89, 132.23, 133.01,
143.53, 152.61, 162.69; IR (KBr) 2980 (m), 1774 (s, C=O), 1602 (s),
1529 (s), 1445 (s), 1380 (s), 1260 (s), 1155 (s), 963 (s), 766 (s) cm21;
HRMS [M + 1] calcd for C17H19N4O2: 311.1508, found 311.1503.
1H-Benzoimidazole-5-Carboxylic Acid Benzotriazol-1-yl Ester, 7
The standard procedure was followed by use of 5-benzimidazole-
carboxylic acid (G5, 39.1 mg, 0.2411 mmol, 1.0 equiv.), HBTU
(100.6 mg, 0.2652 mmol, 1.1 equiv.), and DIEA (46 ml, 0.2652 mmol,
1.1 equiv.). After the reaction mixture was worked up, the residue
was purified by use of column chromatography (chloroform as elu-
ant). Benzotriazole ester 7 (48.5 mg, 0.1737 mmol) was obtained in
72% yield as a light-brown solid: TLC Rf = 0.21 (10% MeOH in
CHCl3 as eluant);
1H NMR (d4-methanol + CDCl3, 400 MHz) d =
7.47–7.53 (m, 2 H, 2 3 ArH), 7.79–7.84 (m, 2 H, 2 3 ArH), 8.04 (d,1 H, J = 8.5 Hz, ArH), 8.17 (dd, 1 H, J = 8.5, 1.6 Hz, ArH), 8.49
(s, 1 H, N=CH), 8.61 (d, 1 H, J = 1.6 Hz, ArH); 13C NMR (d4-methanol +
CDCl3, 100 MHz) d = 108.53, 110.19, 115.19, 117.00, 118.35, 119.38,
124.66, 125.11, 125.96, 126.82, 128.88, 143.11, 144.83, 163.12; IR
(KBr) 3099 (m, NH), 2901 (w), 1778 (s, C=O), 1620 (s), 1576 (m),
1421 (s), 1362 (s), 1281 (s), 1155 (s), 993 (s), 739 (s) cm21; HRMS
[M + 1] calcd for C14H10N5O2: 280.0834, found 280.0834.
1H-Indole-5-Carboxylic Acid Benzotriazol-1-yl Ester, 8
The standard procedure was followed by use of indole-5-carboxylic
acid (70.6 mg, 0.4381 mmol, 1.0 equiv.), HBTU (182.8 mg, 0.4819
mmol, 1.1 equiv.), and DIEA (84 ml, 0.4819 mmol, 1.1 equiv.). After
the reaction mixture was worked up, the residue was purified by
use of column chromatography (chloroform as eluant). Benzotria-
zole ester 8 (107.3 mg, 0.3855 mmol) was obtained in 88% yield as
a brown solid: 1H NMR (d6-acetone, 400 MHz) d = 6.78 (d, 1 H, J =
3.08 Hz,), 7.52 (t, 1 H, J = 7.1 Hz, ArH), 7.59 (t, 1 H, J = 2.3 Hz, ArH),Figure 6. A Modeling Complex of SARS 3CLpro and Benzotriazole Esters
Binding modes of compounds 3 (yellow), 4 (red), 8 (blue), and 9 (green) in the active site of SARS-CoV 3CLpro (PDB luk4). Models were gen-
erated by Autodock and displayed by MGLTOOLS (MGL, Scripps).
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2677.65 (t, 1 H, J = 8.4 Hz, ArH), 7.68 (d, 1 H, J = 8.6 Hz, =CH), 7.79 (d, 1 H,
J = 8.4 Hz, ArH), 8.01 (d, 1 H, J = 8.4 Hz, ArH), 8.10 (d, 1 H, J = 8.6
Hz, =CH), 8.68 (s, 1 H, ArH); 13C NMR (d6-acetone, 100 MHz) d =
104.06, 109.58, 112.82, 115.65, 120.64, 123.78, 125.56, 125.79,
128.53, 128.90, 129.50, 129.78, 141.00, 144.27, 164.87; IR (KBr)
3213 (m, NH), 2907 (w), 1767 (s, C=O), 1614 (s), 1582 (m), 1446 (s),
1359 (s), 1266 (s), 1157 (s), 990 (s), 789 (s) cm21; HRMS [M + 1] calcd
for C15H11N4O2: 279.0882, found 279.0878.
1H-Indole-2-Carboxylic Acid Benzotriazol-1-yl Ester, 9
The standard procedure was followed by use of indole-2-carboxylic
acid (F1, 74.9 mg, 0.4648 mmol, 1.0 equiv.), HBTU (193.9 mg, 0.5113
mmol, 1.1 equiv.), and DIEA (89 ml, 0.5113 mmol, 1.1 equiv.). After the
reaction mixture was worked up, the residue was purified by use of
column chromatography (chloroform as eluant). Benzotriazole ester
9 (115.1 mg, 0.4136 mmol) was obtained in 89% yield as a light-yel-
low solid: TLC Rf = 0.82 (5% MeOH in CHCl3 as eluant);
1H NMR
(CDCl3, 400 MHz) d = 7.24 (t, 1 H, J = 8.0 Hz, ArH), 7.41–7.46 (m, 2
H, 2 3 ArH), 7.49–7.58 (m, 3 H, 3 3 ArH), 7.69 (s, 1 H, =CH), 7.78 (d,
1 H, J = 8.2 Hz, ArH), 8.10 (1 H, J = 8.4 Hz, ArH), 9.97 (br, 1 H, NH);
13C NMR (CDCl3, 100 MHz) d = 38.58, 108.37, 112.48, 113.28,
120.45, 120.69, 121.69, 123.11, 124.90, 127.06, 127.29, 128.83,
138.60, 143.42, 157.99; IR (KBr) 3282 (m, NH), 1773 (s, C=O), 1670
(s), 1517 (s), 1459 (s), 1389 (s), 1340 (s), 1161 (s), 1052 (s), 778 (s)
cm21; HRMS [M + 1] calcd for C15H11N4O2: 279.0882, found
279.0878.
1H-Benzoimidazole-5-Carboxylic Acid
Benzotriazol-1-yl Ester, 10
The standard procedure was followed by use of 5-fluoroindole-2-
carboxylic acid (F4, 26.1 mg, 0.1457 mmol, 1.0 equiv.), HBTU (60.8
mg, 0.1603 mmol, 1.1 equiv.), and DIEA (28 ml, 0.1603 mmol, 1.1
equiv.). After the reaction mixture was worked up, the residue was
purified by use of column chromatography (chloroform as eluant).
Benzotriazole ester 10 (39.3 mg, 0.1327 mmol) was obtained in
91% yield as a light-yellow solid: TLC Rf = 0.83 (5% MeOH in
CHCl3 as eluant);
1H NMR (d6-DMSO and CDCl3, 400 MHz) d = 7.15
(dd, 1 H, J = 7.4, 2.4 Hz, ArH), 7.41–7.52 (m, 3 H, 3 3 ArH), 7.58–
7.65 (m, 2 H, ArH + =CH), 7.71 (d, 1 H, J = 8.4 Hz, ArH), 8.07 (1 H,
J = 8.4 Hz, ArH); 13C NMR (d6-DMSO and CDCl3, 100 MHz) d =
106.15 (d, J = 24.0 Hz), 108.60, 111.92 (d, J = 6.0 Hz), 114.14 (d, J =
10.0 Hz), 115.61 (d, J = 27.0 Hz), 119.66, 121.80, 124.79, 126.35 (d,
J = 11.0 Hz), 128.26, 128.77, 135.58, 142.65, 156.32 (d, J = 235.0
Hz), 157.34; IR (KBr) 3231 (m, NH), 2981 (w), 1782 (s, C=O), 1681
(s), 1521 (m), 1434 (s), 1342 (s), 1222 (s), 1186 (s), 921 (s), 757 (s)
cm21; HRMS [M + 1] calcd for C15H10FN4O2: 297.0779, found
297.0788.
General Procedure for the TBAF-Assisted Benzotriazole
N-Alkylation, 14
Benzotriazole (100 mg, 0.84 mmol) and a-bromo-4-(diethylamino)
acetophenone (272 mg, 1.00 mmol, 1.2 equiv.) were placed in
a 5 ml flask with a stirring bar, followed by the addition of TBAF
(1.00 ml, 0.84 mmol, 1.2 equiv., 1 M in THF) at room temperature.
After being stirred for 2 hr at room temperature, the reaction was di-
rectly loaded into the column, and the product was eluted with a so-
lution of 6:1 hexane:ethyl acetate to yield 217.4 mg (84%) of product
as a pale-yellow solid. 1H NMR (500 MHz, CDCl3) d 8.05 (d, J = 8.5 Hz,
1 H), 7.96 (d, J = 9.2 Hz, 2 H), 7.50–7.30 (m, 3 H), 6.68 (d, J = 9.2 Hz,
2 H), 5.98 (s, 2 H), 3.42 (q, J = 7.0 Hz, 4 H), 1.19 (t, J = 7.0 Hz, 6 H);
13C NMR (125 MHz, CDCl3) d 187.92, 152.46, 146.42, 134.38,
131.37, 128.00, 124.21, 121.41, 120.25, 110.91, 110.46, 53.76,
45.06, 12.87; ESI-MS calculated for C18H20N4O 308.16, found 308.12.
Inhibition Assay against the SARS-CoV 3CL Protease
A fluorometric assay [31] was utilized to determine the inhibition
constants of the prepared samples. Briefly, a fluorogenic peptide,
Dabcyl-KTSAVLQSGFRKME-Edans, was used as the substrate [31],
and the enhanced fluorescence due to cleavage of this substrate
catalyzed by the protease was monitored at 538 nm with excitation
at 355 nm. The IC50 value of individual inhibitors was measured in
a reaction mixture containing 50 nM SARS 3CL protease and 6 mM
fluorogenic substrate in 20 mM Bis-Tris (pH 7.0). The enzyme stock
solution was kept in 12 mM Tris-HCl (pH 7.5) containing 120 mMNaCl, 0.1 mM EDTA, plus 7.5 mM b-ME before being added to the as-
say solution. The Ki measurements (for the noncovalent inhibitors
case) were performed at two fixed inhibitor concentrations and var-
ious substrate concentrations. In the mechanism-based inactivator
cases, we used t1/2 versus 1/[inactivator] for Ki measurements (for
more detailed procedures for the behavior of inhibitors, please see
the Supplemental Data).
Expression and Purification of SARS-CoV 3CLpro
Wild-type and the C145A mutant of the SARS protease were cloned
in pET 28 with N-terminal Trx, His tag, and FXa site. The tags were
removed by FXa protease after the proteins were purified with NiNTA
column chromatography. For more detailed experimental proce-
dures, please see [32].
Mass Spectrometric Analysis
The ESI-MS experiments were conducted on a Bruker Daltonics
BioTOF III high-resolution mass spectrometer, equipped with a
home-built nanoESI source. Mass resolution was better than
20,000 on one-pass mode with a mass range of w100–3,000. The
samples were diluted to 1.0 mM with bidistilled aqueous solution
containing 40% methanol and 0.1% formic acid (v/v/v) and were in-
fused with a syringe pump at a flow rate of 300 nl/min. The actual
amount of samples consumed was less than 300 fmole.
The MALDI-MS measurements were performed on a MALDI-TOF/
TOF mass spectrometer (Applied Biosystems 4700 Proteomics An-
alyzer). Tryptic digest solution was mixed 1:1 with matrix solution
(CHCA [a-cyano-4-hydroxycinnamic acid] 10 mg/ml in solvents
49.9/50/0.1 H2O/CH3CN/TFA), and 1.0 ml was then spotted in each
well. Each MALDI spectrum was accumulated from up to 4,000 laser
shots from a random sampling of 40 positions per well.
Computer Modeling of SARS-CoV 3CL Protease Inhibition
Docking was performed by using Autodock, version 3.05 [30]. Pre-
computed energy grid maps with grid point spacing of 0.375 A˚
and 50 3 50 3 50 grid points centered at the active site were used
(autogrid tool in Autodock, version 3.05). During a docking experi-
ment, each compound was kept flexible (except their rings and am-
ide bonds), and the built-in LGA method was adopted. In each com-
pound structure, 1.53 106 energy was evaluated, and 40 poses were
selected from 2.7 3 105 generations per run.
The crystal structure of SARS-CoV 3CL protease in complex with
a substrate-analog inhibitor (coded 1uk4) was obtained from The
Protein Data Bank (PDB; http://www.rcsb.org/pdb/) (for more de-
tailed procedures, please see the Supplemental Data).
Supplemental Data
Supplemental data including 90 different acids, the X-ray data for
compound 4, synthesis and characterization of compounds 15–20,
a supplemental enzyme kinetic study, and the detailed molecular
docking data are available at http://www.chembiol.com/cgi/
content/full/13/3/261/DC1/.
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